"Quinolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011804
|
| MeSH Number(s) |
D03.633.100.810
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinolines".
Below are MeSH descriptors whose meaning is more specific than "Quinolines".
This graph shows the total number of publications written about "Quinolines" by people in this website by year, and whether "Quinolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 3 | 2 | 5 |
| 2006 | 6 | 1 | 7 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 3 | 5 | 8 |
| 2011 | 2 | 4 | 6 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 3 | 4 |
| 2015 | 4 | 1 | 5 |
| 2016 | 4 | 2 | 6 |
| 2017 | 3 | 0 | 3 |
| 2018 | 3 | 1 | 4 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 1 | 2 |
| 2023 | 1 | 1 | 2 |
| 2024 | 2 | 1 | 3 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinolines" by people in Profiles.
-
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases. J Thorac Oncol. 2026 03; 21(3):103505.
-
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Sep; 26(9):1145-1157.
-
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. J Clin Oncol. 2024 08 20; 42(24):2918-2927.
-
Sirt2 inhibition improves gut epithelial barrier integrity and protects mice from colitis. Proc Natl Acad Sci U S A. 2024 04 30; 121(18):e2319833121.
-
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 03; 34(3):347-359.
-
EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma. Gastroenterology. 2023 05; 164(6):1006-1008.e3.
-
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecol Oncol. 2023 03; 170:172-178.
-
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. Gynecol Oncol. 2022 08; 166(2):351-357.
-
Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. Cancer. 2022 06 15; 128(12):2281-2287.
-
Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2022 07; 179(13):3220-3234.